Evaluating QbD's Impact on the Outsourced Relationship - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating QbD's Impact on the Outsourced Relationship
An Industry Roundtable Moderated by Patricia Van Arnum and Rich Whitworh. Contract service and technology providers share their perspectives on the influence of quality by design in the expectations between sponsor companies and outsourcing providers.

Pharmaceutical Technology
Volume 35, pp. s18-s24

QbD at work

PharmTech : Do you have an example from your own work in which QbD came into play as part of an outsourcing project?

McQuaid (Almac): We have examples where clients have asked us to develop their 'to-be-marketed' formulations. It has been clear from the start of some projects that a QbD approach was desired, so formulation development, analytical development, and process scale-up were all conducted using risk assessment and DoE processes.

Herring (DSM): We are in the final phase (NDA submission) of a QbD project for a new customer in which we provided full formulation, finish dosage, and scale-up activities for a new molecule. The QbD activity was very successful for our customer. We collaborated to identify critical quality characteristics as well as critical process parameters, conducted multivariate analysis, and established in-process specifications to ensure robustness during manufacturing as well as all requirements for the NDA filing.

Lewis (IRIX) : IRIX provided development and manufacturing services for a project using QbD principles to develop and assess risk for manufacturing of a Phase III development API. In preparation for a registration campaign, a two batch demonstration campaign was planned. Prior to the demonstration campaign, IRIX conducted a proven acceptable range (PAR) study for optimization of a hydrogenation step using a new catalyst identified through screening by the catalyst manufacturer. The PAR study compared the process performance of the new catalyst in reaction conditions designed to model the manufacturing process and equipment while using the previous catalyst as a control. IRIX also worked with the client to conduct studies using failure mode and effects analysis (FMEA) of each process step and to incorporate recommendations from those studies in the batch records for the demonstration campaign. A further set of FMEA studies will be conducted prior to the registration campaign using the data collected during the demonstration campaign as well as continued research and development laboratory studies into key areas of concern relative to process control and economics.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here